ArticleJournal of the Endocrine Society2026
Genotype-refined 17OHP cut-offs diagnosing nonclassical CAH due to 21OH deficiency in children with premature pubarche.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genotype-refined 17OHP cut-offs diagnosing nonclassical CAH due to 21OH deficiency in children with premature pubarche.Journal of the Endocrine Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Premature pubarche (PP) is a frequent reason for endocrine evaluation. Between 5% and 20% of children presenting with PP may have 21OHD nonclassic congenital adrenal hyperplasia (21OHD-NCAH). Objective: To define optimal basal and ACTH-stimulated 17OHP cutoffs for diagnosing 21OHD-NCAH in children with PP, using Design setting and patients: A diagnostic accuracy study including 203 children with PP (median age: 7.5 years [6.4-8.3]; 85% female) who underwent ACTH stimulation testing. Biallelic pathogenic variants upon Main outcome measures: Diagnostic performance of basal and post-ACTH 17OHP levels assessed by ROC curve analysis and thresholds defined according to the Youden index. Results: 21OHD-NCAH was confirmed in 32 children (15.7%; 7.1 years [6.1-8.6]; 78% female). Basal 17OHP demonstrated excellent diagnostic accuracy (AUC = 0.98). A cutoff of 170 ng/dL (5.1 nmol/L) provided the best diagnostic balance, with 97% sensitivity and 91% specificity. A higher threshold of 410 ng/dL (12.4 nmol/L) achieved 100% specificity but reduced sensitivity (75%), whereas a lower cutoff of 118 ng/dL (3.5 nmol/L) yielded 100% sensitivity at the expense of specificity (84%). A post-ACTH 17OHP > 1104 ng/dL (33.4 nmol/L) yielded 100% sensitivity and specificity. Androgen levels overlapped substantially, and no clinical feature reliably distinguished 21OHD-NCAH from PP. Conclusion: Basal 17OHP provides excellent diagnostic accuracy for 21OHD-CAH in children with PP. A dual-threshold strategy is supported: 170 ng/dL (5.1 nmol/L) as optimal screening cutoff and 410 ng/d (12.4 nmol/L) as highly specific diagnostic threshold, obviating ACTH testing. These genotype-anchored, RIA-derived cutoffs are readily applicable in clinical settings using comparable assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.